Skip to main content
Journal cover image

The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).

Publication ,  Journal Article
Chen, CLH; Ikram, K; Anqi, Q; Yin, WT; Chen, A; Venketasubramanian, N; NEURITE Investigators,
Published in: Cerebrovasc Dis
2013

BACKGROUND: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have 'vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident dementia, dependency and death. Further studies are urgently needed to demonstrate effective cognition-enhancing therapies in VCIND given the scarcity of evidence-based treatment options. NeuroAiD is a traditional Chinese medicine that has been shown to induce neuroplasticity, promote cell proliferation and stimulate the development of dense axonal and dendritic networks in animal stroke models. NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. OBJECTIVE: To investigate the effects and tolerability of NeuroAiD II in patients with VCIND. METHODS: The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) is a 24-week, double-blind, randomized, placebo-controlled phase II study of NeuroAiD II in patients with VCIND. The primary outcome is executive function as measured by the Verbal Fluency test. Secondary outcomes include cognitive assessments such as the ADAS-Cog, MoCA, MMSE and Cognitive Battery: activities of daily living as measured by the Alzhei-mer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale for mild cognitive impairment, behavior as measured by the Neuropsychiatric Inventory, and depression as measured by the Geriatric Depression Scale and the Beck Depression Scale. In addition, there will be novel exploratory outcomes: (a) magnetic resonance imaging of lesion location (structural imaging), structural integrity of white matter pathways (diffusion tensor imaging), neuronal function (resting studies) and perfusion (arterial spin labeling and MR angiography), and (b) retinal and optic nerve imaging. Safety and tolerability will be assessed using adverse events, laboratory tests and vital signs. CONCLUSIONS: NEURITES has the potential to set new standards for the systematic evaluation of Asian traditional medicine for integration into standard medicine practice and establishing a novel therapeutic approach for improving cognition after stroke.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cerebrovasc Dis

DOI

EISSN

1421-9786

Publication Date

2013

Volume

35 Suppl 1

Start / End Page

23 / 29

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Sample Size
  • Retina
  • Randomized Controlled Trials as Topic
  • Neuropsychological Tests
  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chen, C. L. H., Ikram, K., Anqi, Q., Yin, W. T., Chen, A., Venketasubramanian, N., & NEURITE Investigators, . (2013). The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Cerebrovasc Dis, 35 Suppl 1, 23–29. https://doi.org/10.1159/000346234
Chen, Christopher L. H., Kamran Ikram, Qiu Anqi, Wong Tien Yin, Annabel Chen, Narayanaswamy Venketasubramanian, and Narayanaswamy NEURITE Investigators. “The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).Cerebrovasc Dis 35 Suppl 1 (2013): 23–29. https://doi.org/10.1159/000346234.
Chen CLH, Ikram K, Anqi Q, Yin WT, Chen A, Venketasubramanian N, et al. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Cerebrovasc Dis. 2013;35 Suppl 1:23–9.
Chen, Christopher L. H., et al. “The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).Cerebrovasc Dis, vol. 35 Suppl 1, 2013, pp. 23–29. Pubmed, doi:10.1159/000346234.
Chen CLH, Ikram K, Anqi Q, Yin WT, Chen A, Venketasubramanian N, NEURITE Investigators. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Cerebrovasc Dis. 2013;35 Suppl 1:23–29.
Journal cover image

Published In

Cerebrovasc Dis

DOI

EISSN

1421-9786

Publication Date

2013

Volume

35 Suppl 1

Start / End Page

23 / 29

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Sample Size
  • Retina
  • Randomized Controlled Trials as Topic
  • Neuropsychological Tests
  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Middle Aged
  • Male